ductal carcinoma of the breast in 2007. She received neoadjuvant chemotherapy with dose-dense doxorubicin, cyclophosphamide, and paclitaxel, and subsequently underwent a lumpectomy and axillary lymph node dissection showing residual carcinoma. After whole
Search Results
Namratha Vontela, Vamsi Koduri, Lee S. Schwartzberg, and Gregory A. Vidal
Vijaya Raj Bhatt, Mojtaba Akhtari, R. Gregory Bociek, Jennifer N. Sanmann, Ji Yuan, Bhavana J. Dave, Warren G. Sanger, Anne Kessinger, and James O. Armitage
right breast cancer diagnosed 3 years before presentation, which was treated with mastectomy, sentinel lymph node dissection, and adjuvant cyclophosphamide and doxorubicin (4 cycles); the patient subsequently underwent maintenance therapy with oral
Michelle T. Ashworth and Adil Daud
chest, abdomen, and pelvis identified no other lesions, and results of a complete right inguinal lymph node dissection were negative. The patient was treated with adjuvant radiotherapy (XRT), complicated by a nonhealing ulcer for 1 year and persistent
Michelle C. Nguyen, Manisha H. Shah, David A. Liebner, Floor J. Backes, John Phay, and Lawrence A. Shirley
-oophorectomy and pelvic and periaortic lymph node dissection for stage III uterine carcinosarcoma in March 2016. She completed 6 cycles of carboplatin and paclitaxel therapy and 4,860 cGy of RT to the pelvic and aortic nodes. She later developed subcutaneous
Saranya Chumsri, Ethan S. Sokol, Aixa E. Soyano-Muller, Ricardo D. Parrondo, Gina A. Reynolds, Aziza Nassar, and E. Aubrey Thompson
subsequently underwent right modified radical mastectomy with axillary lymph node dissection. Pathology results showed multifocal residual disease measuring up to 16.5 cm, with >10 additional satellite tumors and skin involvement. Among resected axillary lymph
Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse
omental caking. CA-125 serum tumor marker at time of presentation was elevated at 1,155 kU/L (normal range, <35 kU/L). The patient underwent primary surgery with radical hysterectomy, bilateral salpingo-oophorectomy, lymph node dissection, and removal of
Eleni Efstathiou and Christopher J. Logothetis
-chemotherapy retroperitoneal lymph node dissection . Br J Cancer 1999 ; 80 : 249 – 255 . 55. Howell SJ Shalet SM . Spermatogenesis after cancer treatment: damage and recovery . J Natl Cancer Inst Monogr 2005 ; 34 : 12 – 17 . 56. Brydoy M Fossa SD
Aysegul A. Sahin, Timothy D. Gilligan, and Jimmy J. Caudell
with retroperitoneal lymph node dissection only? Which patients with stage II and III disease will need to undergo resection of residual masses after chemotherapy?” he continued. Dr. Gilligan explained that the 8th edition has made some changes, but
Presenters: Meena S. Moran and A. Marilyn Leitch
avoidance of axillary lymph node dissection (ALND) in many patients. This recommendation is largely based on findings from ACOSOG Z0011 and SINODAR-ONE, in which patients with clinical T1/T2N0 disease with up to 2 positive sentinel nodes fared equally well
Arif Kamal, Tian Zhang, Steve Power, and P. Kelly Marcom
false-positives and unnecessary invasive procedures. 6 – 8 For example, PET/CT has been shown to be less sensitive for the detection of axillary lymph node metastases than axillary lymph node dissection or even physical examination. 9 Finally, advanced